Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Quarterly Revenue and Segment Performance
MDT logo

Medtronic Hits $9 Billion Quarterly Revenue Amid $1.1 Billion Antitrust Verdict and Diabetes Spin-Off

MDT10-QFiling Date: 2/24/2026
Medtronic plc
Description

What this story covers

Medtronic’s Q3 2026 filing reveals $9.0 billion in revenue, driven by Cardiovascular growth. Despite a potential $1.1 billion legal verdict and $185 million tariff headwind, the company maintains strong liquidity as it prepares to spin off its Diabetes business.

Story snapshot

CompanyMedtronic plc
TickerMDT
VariantStandard detailed
Duration12:09
Filing type10-Q
PeriodQ3 2026
IndustryHealthcare & Pharmaceuticals
Accession0001628280-26-011107
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in